9 家券商将 Pliant Therapeutics (NASDAQ:PLRX) 评级为“买入”，平均一年目标价为 49 美元。 9 brokerages rate Pliant Therapeutics (NASDAQ:PLRX) as "Buy" with an average 1-year target price of $49.

9 家经纪公司对 Pliant Therapeutics (NASDAQ:PLRX) 的平均评级为“买入”。 9 brokerages covering Pliant Therapeutics (NASDAQ:PLRX) give an average rating of "Buy". 该股已获得分析师的“买入”一致建议，平均一年目标价为 49 美元。 The stock has received a consensus recommendation of "Buy" from analysts, with an average 1-year target price of $49. 加拿大皇家银行、Needham & Company LLC 和 HC Wainwright 的分析师最近分别给出了“跑赢大盘”、“买入”和“买入”评级，目标价从 38 美元到 54 美元不等。 Analysts from Royal Bank of Canada, Needham & Company LLC, and HC Wainwright have recently issued "outperform", "buy", and "buy" ratings respectively, with price targets ranging from $38 to $54.